Publications by authors named "L J Maness"
Purpose: Sclerotic chronic graft-versus-host disease (cGVHD) represents a highly morbid and refractory form of cGVHD, and novel therapies for sclerotic cGVHD are critically needed. This study aimed to determine the efficacy of ruxolitinib in patients with corticosteroid refractory sclerotic cGVHD.
Patients And Methods: In a single-arm multicenter phase II trial (N = 47), adults with sclerotic cGVHD refractory to corticosteroids and ≥one additional line of systemic therapy for cGVHD received ruxolitinib for ≥six months (ClinicalTrials.
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
February 2024
Article Synopsis
- - Chronic myeloid leukemia (CML) is identified by the Philadelphia chromosome, resulting from a specific genetic change between chromosomes 9 and 22, leading to a unique fusion gene (BCR::ABL1).
- - CML has three phases (chronic, accelerated, and blast), with most diagnoses occurring during the chronic phase in developed regions, and treatment mainly involves tyrosine kinase inhibitors (TKIs) to prevent progression.
- - The manuscript reviews the NCCN Guidelines for diagnosing and managing chronic phase-CML, highlighting that some patients can discontinue TKI therapy under careful supervision.
Introduction: Many older adults with acute myeloid leukemia (AML) do not receive chemotherapy because of physicians' and patients' concern for toxicities and functional decline. This highlights the critical and urgent need to generate knowledge of functional changes following new treatments.
Materials And Methods: As a part of a pragmatic single-center trial, 59 older adults ≥60 years with AML completed geriatric assessment and health-related quality of life measures before treatment and at one month and three months after chemotherapy initiation.
Article Synopsis
- * Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive blood malignancy that involves the rapid growth of specific immune cell precursors and can affect various body parts like bone marrow and skin.
- * The text discusses the diagnosis and treatment of BPDCN according to the National Comprehensive Cancer Network (NCCN) Guidelines for AML.